Extended Release Tablets Formulation Simplified

First time a ‘Ready-to-use’ extended release systems have been developed by ideal Cures Pvt. Ltd. scientists, creating a landmark for innovative solution for extended release tablet formulations. 

Ideal Cures Pvt. Ltd. is the leading player in film coating material manufacturing and technology advancements. Announcing to some of the media people today Mr. Suresh Pareek, Managing Director and main inventor said that, keeping vision of Tomorrow’s Technology Today, first time a ‘Ready-to-use’ extended release systems have been developed by scientists at our new R&D centre, creating a landmark for innovative solution for extended release tablet formulations. Some of the extended release formulations namely Metformin HCl, Diclofenac Sodium, Gliclazide, Paracetamol, Metoprolol, Trimetazidine, Carbamazepine etc. have been successfully developed using INSTAMODEL BLENDS.

Dr Ashok Omray, President and one of the main inventors, outlines that Instamodel extended release composition have been developed with an objective of ‘ready to use system’ and ‘universal acceptability’, according to him Instamodel compositions are not limited to one class of drugs, they could be applied to a broad range of drugs. This ultimately opens a new window for mid-sized pharmaceutical companies worldwide looking for shelf life management of products and offer more convenient treatment options to patients in a shortest possible time frame.

Ideal Cures have product solutions ranging for immediate release to variety of modified release systems, (delayed release, extended/controlled release, sustained release etc.). Extended release drug delivery systems allow release of a therapeutic dose for a longer time with continuous availability to the biological system, thereby reducing the frequency that a patient needs to take the medication. To achieve required extended release delivery pattern a perfect excipients-polymer designing is absolutely essential.

The technology of oral extended release delivery development systems are constantly evolving. Traditionally development of extended release formulations was time consuming elaborated task and involved huge amount of resources. Sensing difficulties faced by mid-sized pharmaceutical organizations team of scientists at Ideal Cures took initiative and devised robust concept of Instamodel. The team of scientists led by Dr. Ashok Omray and guided by Mr. Suresh Pareek, developed Instamodel concept having capability to regulate the drug release by precise design of polymers blend composition along with some GRAS excipients.

Dr. Omray emphasized that, Instamodel systems provide more precise and tailored delivery profile for drugs. INSTAMODEL system is universally applicable with slight developmental inputs in shortest possible time any extended release formulation can be made.

Instamodel offers unmatchable goals to pharmaceutical manufacturers:

  • Almost zero time for formulation development
  • Quick launch to beat the competition
  • Cost effectiveness
  • Simple technology, no additional infra-structure requirements
  • Compliance to multiple Pharmacopeial  standards

Instamodel system has dynamic designing protocol thereby delivering tailor-made formulations. We are proud to say that this is the first time that such a fast result oriented product has been developed, which is completely reliable, reproducible and at par with the regulatory requirements in terms of quality, consistency, and stability. 

Mr. Suresh Pareek and main inventor enlightened that, polymers used are the most common ones having the Pharmacopeial and GRAS status, which have no reported incompatibility with the chosen drug substances. In general they do not present any instability issues. At Ideal Cures we have taken care to ensure that the dissolution behaviour of the product at accelerated and shelf life storage conditions remain unaffected.

Ideal Cures have filed patent applications for present innovations and will expand its base of product by developing a number of several other important compositions. DMF filings will be made to expedite generic development and maximizing regulatory approval chances for mid-sized customers.

Instamodel proprietary product systems of Ideal Cures are developed by designing polymer of high molecular weight or high viscosity like HPMC with other excipients.  Instamodel System is successfully tested and quick to adapt on variety of drugs and nutraceutical products to achieve extended release profile for the drug. According to concept HPMC matrix based formulation highly relies on careful selection of polymer grades, respective diluents and its ratio along with tablet geometry. Ideal Cures screened a large number of polymer matrix systems with other excipients and created exhaustive proprietary database of formulation composition. This database is utilized to generate adaptive formulation for customer’s objective i.e. desired delivery profile.

Illuminating applicability on mid-sized pharmaceutical companies Mr. Suresh Pareek, Managing Director, stated ‘Due to strong generic competition, many of mid-sized pharmaceutical organization will have to evolve their portfolio strategy by adopting to controlled release systems of their older products. Process may require larger time in formulation development but with the use of Instamodel systems phenomenal success could be achieved in shortest possible time. On the other hand for mid-sized generic manufacturers having little or no development capabilities can easily manufacture world-class extended release system through Instamodel systems’.

Ideal Cures has always excellent track record towards customer centric services and support of technical assistance on site. The elaborated stability program will need to be developed and stability studies will be performed at the customer end for complete documentation. The technical support for the familiarization and initial stability/commercial batches will be provided by ideal cures along with quantities of the Instamodel blends. 

For further information please contact –

Ideal Cures Pvt. Ltd.

Mail:- pareeksuresh@idealcures.co.in  / ashokomray@idealcures.co.in

Phone:- 91 22 42688700

Web:- www.idealcures.co.in

Postal Address,

India HO and Technical Center:- A-223 to A-229, 2nd Floor, Virwani Industrial Estate, Off Western Express Highway, Goregaon (East), Mumbai-400 063, India

Europe SRL:- Ideal Cures Europe SRL, Via Quintiliano, 30 ; 20138 - Milano Italy.

Ideal Cures Pvt. Ltd. is self-sustaining Indian Organization with Global reach to more than 36 countries with subsidiary Ideal Cures Europe SRL, Europe.  Ideal Cures has three cGMP manufacturing plants in India providing world-class support to Indian as well as foreign pharmaceutical organizations. Ideal Cures Pvt. Ltd. is perceived as major alternate supplier for the film coating system by many multinational companies, which offers them superior technical services and support with competitive product prices. Ideal Cures has reputation of meeting quality requirement at par of pharmaceutical industry and regulatory bodies. Ideal Cures has spent a decade in its relentless pursuit of excellence in finding tailor-made excipients and coating solutions for solid dosage forms. From ready to use Film Coating Systems, Modified release Technologies, NDDS and Acrylic Pharma Polymers to Extended Cooling Boosters and Neutral Spheres.

Tags:

Quick facts

First time a ‘Ready-to-use’ extended release systems have been developed by Ideal cures Pvt. Ltd.
Tweet this

Quotes

Keeping vision of Tomorrow’s Technology Today, first time a ‘Ready-to-use’ extended release systems have been developed by scientists at our new R&D centre, creating a landmark for innovative solution for extended release tablet formulations.
Mr. Suresh Pareek, Managing Director
Instamodel extended release composition have been developed with an objective of ‘ready to use system’ and ‘universal acceptability’, according to him Instamodel compositions are not limited to one class of drugs, they could be applied to a broad range of drugs.
Dr. Ashok Omray, President